Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3

Indication details

Combined Agent(s)
Nivolumab
Control Arm
Nivolumab
Therapeutic Indication
First line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression <1%.
Tumour Type
Skin Cancers
Tumour Sub-type
Cutaneous Melanoma
Tumour Stage
Unresectable or metastatic
Tumour Sub-Group
PD-L1 expression <1%
Trial Name
RELATIVITY-047
NCT Number
NCT03470922
Trial Phase
Phase II/III

Approval details

EMA Approval
EMA (CHMP) July 2022 EC decision September 2022

Primary Outcome(s)

Primary Outcome(s)
PFS
Evaluated Outcome
PFS
Form(s)
Form 2b

Outcome Data

PFS Control
2.9 months
PFS Gain
3.5 months
PFS HR
0.66 (0.51-0.84)

Adjustments

QoL Comment
QoL was an exploratory endpoint

Score (after adjustments)

Preliminary non-curative score

3

Non-curative score

3

Comment
EMA (CHMP) July 2022 EC decision September 2022

The long-term benefit seems promising and the melanoma paradigm suggests that the experimental curve will likely plateau. A longer follow-up would confirm whether this study is eligible for a final score of 4 based on a plateau bonus (>10% improvement at 2-years).

Scorecard details

ESMO-MCBS version
ESMO-MCBS v1.1
Scorecard ID
366
Scorecard version
1
Issue date
11.01.2023
Relatlimab RELATIVITY-047

PRELIMINARY SCORE

PFS

ADJUSTMENTS

Relatlimab RELATIVITY-047

SCORE

Overall Survival / Disease-Free Survival / Pathological Complete Response
Overall Survival
3
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Skin Cancers
First line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression <1%.
Relatlimab + Nivolumab
Nivolumab

My watchlist

    pdf
    pptx

    Legend

    Information about symbols, abbrevations and color codes

    Red = negative
    Green = positive
    Grey = neutral
    ? Grey + ? = neutral with pending data
    DFS
    Disease-Free Survival
    DoR
    Duration of Response
    EFS
    Event-Free Survival
    HR
    Hazard Ratio
    NEB
    No evaluable benefit
    NI
    Non-inferiority Study
    ORR
    Overall Response Rate
    OS
    Overall Surival
    pCR
    Pathological Complete Response/Remission
    PFS
    Progression-Free Survival
    QoL
    Quality of Life
    RFS
    Relapse-Free Survival
    RR
    Response Rate

    QoL adjustments

    Other adjustments*

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    QoL adjustments

    Red = negative / deterioration

    Green = positive / improvement

    Other adjustments*

    Red = negative / deterioration

    Green = positive / improvement

    Serious and disabling adverse effects

    Red = negative / deterioration

    Green = positive / improvement

    * Other adjustments include:

    - Long-term plateau in the survival curve
    - Long-term plateau in the PFS curve
    - Early stopping or crossover
    - Only improved PFS mature data shows no OS advantage and no improved Qol.

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.